Active, not recruitingPhase 1NCT05544929
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Studying Nasopharyngeal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- KFA115(drug)
- Enrollment
- 126 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2022 – 2027
Study locations (19)
- Massachusetts General Hospital ., Boston, Massachusetts, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- NYU School of Medicine, New York, New York, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- Novartis Investigative Site, Toronto, Ontario, Canada
- Novartis Investigative Site, Guangzhou, Guangdong, China
- Novartis Investigative Site, Beijing, China
- Novartis Investigative Site, Lyon, France
- Novartis Investigative Site, Dresden, Saxony, Germany
- Novartis Investigative Site, Essen, Germany
- Novartis Investigative Site, Hong Kong, Hong Kong
- Novartis Investigative Site, Milan, MI, Italy
- Novartis Investigative Site, Modena, MO, Italy
- Novartis Investigative Site, Chuo Ku, Tokyo, Japan
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05544929 on ClinicalTrials.govOther trials for Nasopharyngeal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980038Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07362979Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaSun Yat-sen University
- RECRUITINGNANCT06796270Hypofractionated Radiotherapy for Nasopharyngeal CarcinomaThe Second Affiliated Hospital of Hainan Medical University
- RECRUITINGPHASE2NCT06059261Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.Chongqing University Cancer Hospital
- RECRUITINGNCT07376603IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesQiaojuan Guo
- RECRUITINGPHASE3NCT07340515Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialMan Hu
- RECRUITINGNCT07232680Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon ChemoradiotherapyCheng-En Hsieh
- RECRUITINGPHASE3NCT0732885440.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaMing-Yuan Chen